Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pCe6 is a synthetic photosensitizer designed for targeted photodynamic therapy (PDT) with a specific focus on the endoplasmic reticulum (ER). It is chemically synthesized by conjugating Chlorin e6 (Ce6), a second-generation photosensitizer, with p-Toluenesulfonamide, which acts as an ER-targeting moiety. By localizing to the ER, pCe6 induces significant ER stress and reactive oxygen species (ROS) production upon light activation, leading to cancer cell apoptosis and immunogenic cell death. In preclinical research, pCe6 has been incorporated into hyaluronic acid-modified nanoplatforms (such as HA/pCe6-Ato NPs) to treat colorectal cancer. This strategy aims to dismantle cancer stemness and reprogram the immunosuppressive tumor microenvironment, thereby enhancing the efficacy of immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pCe6.